Good Laboratory Practice (GLP) status of Asian countries and its implementation in non-clinical safety studies in pharmaceutical drug development

Madoka Sasaki, Shiro Hinotsu, Koji Kawakami

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Non-clinical animal studies to assess the safety of compounds under development have to comply with Good Laboratory Practice (GLP). The Organization for Economic Co-operation and Development (OECD) has established the Mutual Acceptance of Data (MAD) system in OECD member countries for the mutual acceptance of non-clinical safety study data. Since 1997 non-OECD-member countries have also been able to participate in the MAD system, if the country meets the level of standardized compliance with OECD GLP. Thus, several Asian non-OECD countries are trying to develop their GLP standards in order to become official members of the MAD system. Pharmaceutical companies face significant expense in the drug-development process, including the cost of non-clinical safety studies; in response, companies in Asian countries are seeking to establish GLP facilities to provide cost-effective services for drug development. To assess the quality and cost of GLP performance in Asian countries, in this study we approached GLP facilities in a number of Asian countries to obtain price and quality information on a 'virtual compound' to be assessed in non-clinical safety studies. Also, the development status of GLP in Asian countries in terms of policy and infrastructure was analyzed. We found that, among Asian countries, India and Singapore may be candidates for participation in the MAD system in terms of their compliance with GLP, language, and costs. These findings will be beneficial to pharmaceutical companies planning GLP studies in Asian countries.

Original languageEnglish
Pages (from-to)493-500
Number of pages8
JournalJournal of Toxicological Sciences
Volume34
Issue number5
DOIs
Publication statusPublished - Oct 2009
Externally publishedYes

Fingerprint

Safety
Pharmaceutical Preparations
Information Systems
Economics
Costs and Cost Analysis
Costs
Industry
Singapore
India
Animals
Language
Planning
Organisation for Economic Co-Operation and Development

Keywords

  • Asian countries
  • GLP
  • MAD system
  • Non-clinical safety study
  • Pharmaceutical development

ASJC Scopus subject areas

  • Toxicology

Cite this

Good Laboratory Practice (GLP) status of Asian countries and its implementation in non-clinical safety studies in pharmaceutical drug development. / Sasaki, Madoka; Hinotsu, Shiro; Kawakami, Koji.

In: Journal of Toxicological Sciences, Vol. 34, No. 5, 10.2009, p. 493-500.

Research output: Contribution to journalArticle

@article{86c16236f8b9483a983bb015ff3e97d4,
title = "Good Laboratory Practice (GLP) status of Asian countries and its implementation in non-clinical safety studies in pharmaceutical drug development",
abstract = "Non-clinical animal studies to assess the safety of compounds under development have to comply with Good Laboratory Practice (GLP). The Organization for Economic Co-operation and Development (OECD) has established the Mutual Acceptance of Data (MAD) system in OECD member countries for the mutual acceptance of non-clinical safety study data. Since 1997 non-OECD-member countries have also been able to participate in the MAD system, if the country meets the level of standardized compliance with OECD GLP. Thus, several Asian non-OECD countries are trying to develop their GLP standards in order to become official members of the MAD system. Pharmaceutical companies face significant expense in the drug-development process, including the cost of non-clinical safety studies; in response, companies in Asian countries are seeking to establish GLP facilities to provide cost-effective services for drug development. To assess the quality and cost of GLP performance in Asian countries, in this study we approached GLP facilities in a number of Asian countries to obtain price and quality information on a 'virtual compound' to be assessed in non-clinical safety studies. Also, the development status of GLP in Asian countries in terms of policy and infrastructure was analyzed. We found that, among Asian countries, India and Singapore may be candidates for participation in the MAD system in terms of their compliance with GLP, language, and costs. These findings will be beneficial to pharmaceutical companies planning GLP studies in Asian countries.",
keywords = "Asian countries, GLP, MAD system, Non-clinical safety study, Pharmaceutical development",
author = "Madoka Sasaki and Shiro Hinotsu and Koji Kawakami",
year = "2009",
month = "10",
doi = "10.2131/jts.34.493",
language = "English",
volume = "34",
pages = "493--500",
journal = "Journal of Toxicological Sciences",
issn = "0388-1350",
publisher = "Japanese Society of Toxicological Sciences",
number = "5",

}

TY - JOUR

T1 - Good Laboratory Practice (GLP) status of Asian countries and its implementation in non-clinical safety studies in pharmaceutical drug development

AU - Sasaki, Madoka

AU - Hinotsu, Shiro

AU - Kawakami, Koji

PY - 2009/10

Y1 - 2009/10

N2 - Non-clinical animal studies to assess the safety of compounds under development have to comply with Good Laboratory Practice (GLP). The Organization for Economic Co-operation and Development (OECD) has established the Mutual Acceptance of Data (MAD) system in OECD member countries for the mutual acceptance of non-clinical safety study data. Since 1997 non-OECD-member countries have also been able to participate in the MAD system, if the country meets the level of standardized compliance with OECD GLP. Thus, several Asian non-OECD countries are trying to develop their GLP standards in order to become official members of the MAD system. Pharmaceutical companies face significant expense in the drug-development process, including the cost of non-clinical safety studies; in response, companies in Asian countries are seeking to establish GLP facilities to provide cost-effective services for drug development. To assess the quality and cost of GLP performance in Asian countries, in this study we approached GLP facilities in a number of Asian countries to obtain price and quality information on a 'virtual compound' to be assessed in non-clinical safety studies. Also, the development status of GLP in Asian countries in terms of policy and infrastructure was analyzed. We found that, among Asian countries, India and Singapore may be candidates for participation in the MAD system in terms of their compliance with GLP, language, and costs. These findings will be beneficial to pharmaceutical companies planning GLP studies in Asian countries.

AB - Non-clinical animal studies to assess the safety of compounds under development have to comply with Good Laboratory Practice (GLP). The Organization for Economic Co-operation and Development (OECD) has established the Mutual Acceptance of Data (MAD) system in OECD member countries for the mutual acceptance of non-clinical safety study data. Since 1997 non-OECD-member countries have also been able to participate in the MAD system, if the country meets the level of standardized compliance with OECD GLP. Thus, several Asian non-OECD countries are trying to develop their GLP standards in order to become official members of the MAD system. Pharmaceutical companies face significant expense in the drug-development process, including the cost of non-clinical safety studies; in response, companies in Asian countries are seeking to establish GLP facilities to provide cost-effective services for drug development. To assess the quality and cost of GLP performance in Asian countries, in this study we approached GLP facilities in a number of Asian countries to obtain price and quality information on a 'virtual compound' to be assessed in non-clinical safety studies. Also, the development status of GLP in Asian countries in terms of policy and infrastructure was analyzed. We found that, among Asian countries, India and Singapore may be candidates for participation in the MAD system in terms of their compliance with GLP, language, and costs. These findings will be beneficial to pharmaceutical companies planning GLP studies in Asian countries.

KW - Asian countries

KW - GLP

KW - MAD system

KW - Non-clinical safety study

KW - Pharmaceutical development

UR - http://www.scopus.com/inward/record.url?scp=70349934724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349934724&partnerID=8YFLogxK

U2 - 10.2131/jts.34.493

DO - 10.2131/jts.34.493

M3 - Article

C2 - 19797857

AN - SCOPUS:70349934724

VL - 34

SP - 493

EP - 500

JO - Journal of Toxicological Sciences

JF - Journal of Toxicological Sciences

SN - 0388-1350

IS - 5

ER -